TITLE

Why should clinical trials be registered?

PUB. DATE
June 2005
SOURCE
CMAJ: Canadian Medical Association Journal;6/21/2005, Vol. 172 Issue 13, p1653
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Comments on the reasons why clinical trials should be registered. Benefits of trial registration; View of pharmaceutical companies on public disclosure.
ACCESSION #
17290880

 

Related Articles

  • Credible Lit. Baiter, Wendy; Scott, Marsha // Pharmaceutical Executive;Aug2006, Vol. 26 Issue 8, p138 

    The article focuses on several developments in report publications in the pharmaceutical industry in the U.S. Review article development is moving together with the most forward-thinking companies developing internal guidelines that leave content development to the author. Another development is...

  • Transparency and Registries. Hindin, Toby Jane // Applied Clinical Trials;Apr2005, Vol. 14 Issue 4, p12 

    Reports on a number of drug companies who are taking the lead in setting up trial registries in the U.S. Impact of the disclosure of serious adverse events on public confidence in the pharmaceutical industry; Recommendation on the need for transparency in clinical trials; Efforts of industry...

  • Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. De Angelis, Catherine; Drazen, Jeffrey M.; Frizelle, Frank A.; Haug, Charlotte; Hoey, John; Horton, Richard; Kotzin, Sheldon; Lame, Christine; Marusic, Ana; Overbeke, A. John P. M.; Schroeder, Torben V.; Sox, Harold C.; Van Der Weyden, Martin B. // Journal of Rehabilitation Research & Development;Jul/Aug2005, Vol. 42 Issue 4, preceding p1 

    The article reports that in September 2004, the members of the International Committee of Medical Journal Editors published a joint editorial aimed at promoting registration of all clinical trials. This policy applies to trials that start recruiting on or after July 1, 2005. A complete registry...

  • Clinical Trials Research in Pediatrics: Strategies for Effective Collaboration Between Investigator Sites and the Pharmaceutical Industry. Bush, Andrew // Pediatric Drugs;2006, Vol. 8 Issue 5, p271 

    There is a paucity of clinical trials work in children, which leads to the frequent use of off-label and unlicensed medications in this very vulnerable group. Clinical trials work in children may be more difficult than in adults, and there are certainly ethical constraints. However, the...

  • Pharma Urged to Register Early Trials. Mitchell, Pete // Pharma DD: Tracking Discovery & Development;Jul/Aug2006, Vol. 1 Issue 1, p20 

    The article focuses on the proposal of the World Health Organization (WHO) concerning the publication of plans for all clinical trials by pharmaceutical companies on the Internet that include early-stage proof-of-concept studies. WHO requires all medical studies that test treatments on human...

  • Major Medical Journals Will Require That Randomized Trials Be Registered.  // AIDS Treatment News;6/24/2005, Issue 413, p6 

    Comments on the refusal of some drug companies to comply with the registration of randomized trials to avoid disclosing their activities to their competitor. Mandate of medical journals that they will consider a trial for publication only if it has been registered before enrollment of the first...

  • CULTURE CLUBS. Kibby, Matthew // Pharmaceutical Executive;Apr2006, Vol. 26 Issue 4, p106 

    The article reports on the role of ethics committees in a worldwide clinical trial. Their review systems are crucial to the development of global regulatory climate concerning patient-recruitment advertising. They are also consigned with ensuring protection, safety and welfare of clinical trial...

  • Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy. Ranjan, Amalendu P.; Mukerjee, Anindita; Helson, Lawrence; Vishwanatha, Jamboor K. // Journal of Nanobiotechnology;2012, Vol. 10 Issue 1, p38 

    Background: Nanoparticle based delivery of anticancer drugs have been widely investigated. However, a very important process for Research & Development in any pharmaceutical industry is scaling nanoparticle formulation techniques so as to produce large batches for preclinical and clinical...

  • ABANDON PAPER! USE A PDA! Uehling, Mark D. // Bio-IT World;Jun2005, Vol. 4 Issue 6, p48 

    Focuses on the trend among pharmaceutical companies to use personal digital assistants to record patient diaries in clinical trials. Range of prices of electronic gadgets used in clinical trials; Effective use of electronic diary by Amylin Pharmaceutical in the clinical trial for its Symlin...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics